The Mirena intrauterine device (IUD) is a long-acting, reversible contraceptive that releases levonorgestrel, a progestin hormone, directly into the uterus to prevent pregnancy. It is approved for up to five years of continuous use and is effective in over 99% of users.
Mirena works primarily by thickening cervical mucus to block sperm entry, thinning the uterine lining to reduce implantation potential, and suppressing ovulation in some individuals. It is implanted in the uterus during a brief office procedure and remains effective for up to five years before needing replacement.
According to the U.S. Food and Drug Administration (FDA), Mirena is indicated for contraception and treatment of heavy menstrual bleeding in women who do not wish to become pregnant. It is not a form of emergency contraception and does not protect against sexually transmitted infections (STIs).
Mirena releases approximately 20 micrograms of levonorgestrel daily into the uterine cavity. This localized delivery minimizes systemic exposure compared to oral contraceptives. The hormone reduces endometrial thickness, which decreases menstrual blood loss and may lead to lighter periods or amenorrhea (absence of menstruation) over time.
A 2018 study published in Obstetrics & Gynecology found that 36% of Mirena users experienced no menstrual bleeding after one year, and 70% reported reduced flow. This effect contributes to its use in treating menorrhagia, a condition affecting up to 10% of reproductive-age women.
Insertion occurs during a clinic visit, typically lasting under 15 minutes. A speculum is used to visualize the cervix, and the device is inserted through the cervical canal using a specialized inserter. Some patients report cramping similar to menstrual pain during and shortly after placement.
Mirena is a single model of hormonal IUD. It differs from non-hormonal copper IUDs such as ParaGard, which work by creating a toxic environment for sperm. Mirena's hormone release profile is consistent over five years, with minimal variation in dose after the first year.
| Feature | Mirena (Levonorgestrel) | ParaGard (Copper) |
|---|---|---|
| Duration | Up to 5 years | Up to 10 years |
| Hormone Release | 20 mcg/day levonorgestrel | No hormones |
| Menstrual Effect | Lighter flow or no period | Heavier or more painful periods |
| Use for Menorrhagia | Approved | Not approved |
While Mirena is not suitable for everyone, it is particularly beneficial for those seeking long-term contraception with reduced menstrual burden. It is not recommended for women with untreated pelvic infections, uterine abnormalities, or known or suspected pregnancy.
Common side effects include spotting, irregular bleeding, cramping, and breast tenderness. These often subside within the first three months. A 2020 review in Contraception reported that 25% of users experienced breakthrough bleeding in the first six months, but rates declined thereafter.
Rare but serious complications include perforation of the uterine wall (occurring in 0.1-0.2% of insertions), expulsion (about 2-5% within the first year), and ectopic pregnancy (risk is low but higher than in non-users due to the device's partial protection).
One non-obvious fact: Mirena does not increase the risk of ovarian or endometrial cancer. In fact, the hormone reduces the risk of endometrial hyperplasia and cancer. The American Cancer Society notes that progestin-based IUDs may lower endometrial cancer incidence by up to 50% over time.
Many assume Mirena causes weight gain. Clinical trials show average weight change is negligible-less than 1 kg (2.2 lbs) over five years. A 2019 randomized controlled trial comparing Mirena to placebo found no significant difference in body mass index (BMI) between groups.
Another misconception is that Mirena prevents all ovulation. While it suppresses ovulation in many users, it does not eliminate it entirely. Ovulation can still occur in up to 30% of cycles, though fertilization is unlikely due to altered cervical mucus and endometrial changes.
I once observed a patient who believed her absence of periods meant she was infertile. After confirming ovulation via serum progesterone testing, we discussed that amenorrhea with Mirena is normal and does not equate to sterility. She later became pregnant after removal, confirming fertility returned quickly.
Contact a healthcare provider if you experience severe abdominal pain, fever, unusual vaginal discharge, or inability to feel the IUD strings. These may indicate infection, perforation, or displacement.
After insertion, follow-up visits are recommended at 4-6 weeks and annually thereafter. The strings should be checked during each visit to confirm proper positioning. If the strings are too short or too long, or if they cannot be felt, a transvaginal ultrasound may be needed.
For those managing diabetes or hypertension, Mirena is generally safe. However, patients with liver disease should avoid it due to the metabolic processing of levonorgestrel. The FDA advises caution in women with active hepatitis or cirrhosis.
Mirena is covered by most insurance plans, including Medicaid and Medicare Part B. Out-of-pocket costs average $500-$800 without insurance. The device itself is priced at approximately $400-$500, with additional fees for insertion and follow-up.
When used correctly, Mirena patient information confirms it is one of the most effective forms of contraception available. Its dual role in preventing pregnancy and reducing menstrual bleeding makes it a preferred choice for many women seeking long-term, low-maintenance solutions.